Aldurazyme
What Aldurazyme is used for
Aldurazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis I (MPS I; alpha-L-iduronidase deficiency) to treat the nonneurological manifestations of the disease.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Aldurazyme
- Active substance
- laronidase
- Disease area
- Mucopolysaccharidosis I
- Medicine group
- Other alimentary tract and metabolism products
- ATC code
- A16AB05
- Marketing authorisation holder
- Sanofi B.V.
- Authorised in the EU since
- 2003
Official information
In the USA
Same active substance: Aldurazyme
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Aldurazyme used for?
Aldurazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis I (MPS I; alpha-L-iduronidase deficiency) to treat the nonneurological manifestations of the disease.
What is the active substance in Aldurazyme?
Aldurazyme contains laronidase.
Who makes Aldurazyme?
The EU marketing authorisation holder is Sanofi B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU